News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
16 Sep 2022
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.
16 Sep 2022

Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
16 Sep 2022
byStephen Padilla
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
16 Sep 2022

Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
16 Sep 2022
Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.
16 Sep 2022





